Tumor sample context
Tumor type, collection site, sample condition, expected timing and available ethics documentation.
HCC PDO / PDO 2.0
Use conventional PDOs for HCC efficacy studies. Immunotherapy or anti-angiogenic programs can add PDO 2.0, vascular-marker profiling or a purpose-built co-culture.
AlbuminCK19CD8NKTAM
Model source
Patient HCC tissue
Culture / format
PDO · ALI · Immune co-culture study format
Supporting evidence
TRiCBIO HCC PDO study data
Model characterization
How the model is established and characterized
Source-tissue and organoid imaging plus lineage/identity markers characterize the model; functional readouts are selected for the candidate mechanism and study objective.
View imageConventional PDO culture: bright-field and whole-mount immunofluorescence show model morphology and cell state, supporting characterization and downstream endpoint design.
Study data
View imageTissue and model profiling: paired H&E, CD31 and HEP-1 immunohistochemistry in source tissue and PDO shows tissue architecture, vascular features and hepatic lineage markers, supporting model identity and the selection of target and mechanism readouts.
Model & assay dataStudy planning
From study objective to model and assay plan
Tumor type, sample condition, candidate and intended comparison guide the culture format, controls and assays.
Candidate and study objective
Modality, dosing plan, controls and the response or comparison the study should address.
Assays and deliverables
Planned histology, flow, molecular or functional assays, together with preferred data and report formats.
Study design
Interpret HCC drug response from tissue and model identity
HCC PDO studies combine source tissue, model identity, immune or vascular context and treatment response, connecting activity readouts with tissue biology to explain differences among candidates.
Confirm source and pathology
Review the documented liver-tumor pathology, sampling site, prior treatment and available pathology.
Compare tissue and model
Use H&E and hepatic, epithelial or endothelial markers to confirm that the model is ready for efficacy work.
Design treatment around mechanism
Set doses, time points and controls around small-molecule, ICB, anti-angiogenic or combination mechanisms.
Interpret response in context
Compare candidates using viability, histology, immune composition, cytokine or flow results in context.
Research applications
Recommended applications
- Candidates and combinations
- ICB and anti-angiogenic mechanism studies
- Tumor, immune and vascular-marker profiling
Assays & QC
Tumor identity, efficacy and immune readouts
Key markers
AlbuminCK19CD8NKTAM
Available assays
- H&E / IF
- Flow cytometry
- Viability
- Cytokines
QC approach
Hepatic identity and tissue architecture establish the model baseline, followed by immune, vascular-marker and functional readouts matched to the selected system.
Study & delivery
Model characterization, treatment data and reporting
Choose a supplied model or a TRiCBIO-run efficacy and mechanism study. Typical deliverables include imaging, assay data, analysis and a study report.
Related solutions
Related study options
PROJECT DISCUSSION
Discuss a HCC PDO / PDO 2.0 study
Tumor type, sample status, candidate profile and comparison endpoints determine the culture format, controls, assay panel and deliverables for the HCC PDO / PDO 2.0.